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for dyspepsia. Age, gender, education, physical and mental health, pain,
disability, and locus of control were not associated with MARI.
Conclusions: This study quantiﬁed osteoarthritis patients’ preferences
toward trade-offs between the risk of speciﬁc side effects of treatment
and pain relief. As expected, the average additional risk that would be
acceptable to subjects varied by side effect and increased in conjunction
with the amount of potential pain relief. For all side effects, the acceptable
level of risk for a given level of pain relief varied substantially among
the subjects. Demographic, clinical, and psychological factors did not
explain the variation in trade-off preferences. The study demonstrated the
usefulness of the probabilistic threshold technique in eliciting preferences
for trade-offs between the risk of side effects and pain relief. These
observations are important for the development of practice guidelines
for physicians and patients’ decision aids that can foster individualized,
evidence-based yet preference-sensitive care for patients with OA.
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Purpose: No treatments capable of slowing the osteoarthritic process
have been identiﬁed so far. Intra-articular treatment is a promising new
approach that targets locally released cytokines and proinﬂammatory
mediators in the synovial ﬂuid. Furthermore, intra-articular treatment may
be the best way to access the cartilage and synovial membrane and offers
a better risk-beneﬁt ratio than systemic treatment.
Methods: Large review of the literature concerning i.a therapies was
performed excluding current intra-articular treatments which are available,
namely, glucocorticoid injection, hyaluronic acid injection, and joint lavage.
Results: Targeted treatments designed to restore the balance between
prodegradative cytokines and anabolic factors must be developed. Il-1 b
and TNFa are the most powerful cytokines in OA. Cytokine blockers
can be injected intra-articularly, either directly or via gene therapy. Intra-
articular injection of Il-1 receptor antagonist (Il-1-ra) produced promis-
ing results in animal models of OA. Il-1-ra injection is well tolerated
in humans. However, in the only randomised controlled trial, a single
Il-1-ra (50 or 150mg) injection for knee osteoarthritis had little effect,
possibly because of the short half-life of this cytokine antagonist. Intra-
articular TNFa antagonist therapy has not been evaluated in clinical
trials in humans. Downstream from Il-1b and TNFa, caspases can be
blocked by direct injection of caspase inhibitors. Synovitis is thought
to be involved in OA progression and therefore constitutes a major
target. Depletion of synovial-membrane macrophages is associated with
decreased metalloproteinase expression. Injection of an agent that blocks
bone remodelling is an original and appealing approach. In mice, intra-
articular injection of osteoprotegerin decreased the severity of OA le-
sions. Injection of anabolic factors might promote cartilage repair, thereby
slowing the osteoarthritic process. Intra-articular injection of encapsulated
bFGF microspheres holds some promise. TGFb is an extremely powerful
stimulant of cartilage repair but also induces synovial membrane ﬁbrosis
and osteophyte growth. To avoid these adverse effects, gene therapy
using both TGFb and Smad 7 has been used in experimental models of
OA. The short half-lives of growth factors and cytokine antagonists indi-
cates a need for developing new delivery strategies, such as liposomes,
microspheres, and gene therapy, all of which exhibit limitations.
Conclusions: Intra-articular therapy holds promise for the treatment of
OA, although many issues await resolution.
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Purpose: The purpose of cartilage functional tissue engineering is to
produce a tissue whose mechanical properties allow it to sustain the
physiological load magnitudes encountered in vivo. Based on our under-
standing of cartilage mechanics, these properties are critically dependent
on the proteoglycan and collagen content of engineered cartilage, as well
as the ultrastructural organization of the collagen matrix.
Methods: Recent in vitro tissue engineering studies of bovine
chondrocyte-seeded agarose constructs have demonstrated that it is
possible to produce native levels of proteoglycans (~6% w/w) in 4 to
8 weeks. These results are achieved by using a chemically deﬁned
chondrogenic culture medium with administration of TGF-b3 over the ﬁrst
two weeks. The resulting equilibrium compressive mechanical properties
of the constructs match the values of native cartilage. However, collagen
content levels (~4% w/w) remain below native levels (~15% w/w), and
various strategies have been explored to further increase collagen syn-
thesis. This lower collagen content is believed to be the primary reason
that compressive properties of cartilage under dynamic loading remain
below native levels.
Results: Under these conditions, animal studies have shown that tissue
constructs show a variable ability to survive physiological loading condi-
tions in vivo. Implanted small cylindrical constructs that are buttressed by
healthy host cartilage show encouraging outcomes, whereas complete
resurfacing of an articular layer with an anatomically shaped tissue
construct fares more poorly.
Conclusions: These ﬁndings emphasize the need for functional tissue
engineering that can reproduce the mechanical properties of native
cartilage prior to in vivo implantation. The most critical need at this
time is the necessity to increase collagen content to native levels, to
improve the compressive properties of tissue constructs under dynamic
loading. Some of our recent studies show that improvements in collagen
synthesis may be achieved by delaying the relatively rapid accumulation
of proteoglycans, using selective and timely enzymatic degradation.
I-12 VALUE OF AUTOLOGOUS CELL TRANPLANTATION IN THE
TREATMENT OF OSTEOARTHRITIS
A. Facchini1, B. Grigolo2, G. Lisignoli2, C. Cavallo1, G. Desando1,
G. Giavaresi2, M. Fini2, R. Giardino1. 1Istituto Ortopedico
Rizzoli/University of Bologna, Bologna, ITALY , 2Istituto Ortopedico
Rizzoli, Bologna, ITALY
Purpose: Chondrocyte transplantation (ACT) has been a widely used
clinical strategy in the repair of damaged cartilage from lesions resulting
from traumatic injuries. In the last decade good clinical results have been
obtained together with the formation of a new tissue with many hyaline
features. More recently, suitable scaffolds loaded with chondrocytes have
been used to hold the cells in the defect site, thus, permitting their prolifer-
ation, differentiation and maintenance of the chondrocyte phenotype. We
explored the ACTapproach to treat osteoarthritis (OA) lesions by using an
experimental animal model of OA into which autologous marrow-derived
mesenchymal stem cells (MSCs) were seeded onto a hyaluronan-based
scaffold (Hyaff®-11, Fidia Advanced Biopolymers, Abano Terme, PD, Italy)
that was surgically positioned on the cartilages lesions of the knee.
Methods: Rabbit knee joints were bilaterally subjected to anterior cruciate
ligament transection (ACLT) to surgically induce OA. Autologous rabbit
MSCs have been isolated from the bone marrow, expanded in vitro and
loaded on a hyaluronan polymeric scaffold (Hyaff®-11). After 8 weeks,
necessary to the development of cartilage surface damage, animals were
treated with MSCs seeded onto Hyaff®-11 scaffold in the left condyle
and unseeded Hyaff®-11 in the controlateral knee. Untreated (sham
operated) rabbits with ACTL were used as control. All the animals were
sacriﬁced at 3 and 6 months after surgery. Morphological, histological,
histomorphometric and immunohistological evaluations were performed.
Results: OA changes developed in all animals subjected to ACLT. The
predominant macroscopically observed OA changes were mild (lateral
femoral condyle) or moderate (medial femoral condyle) ulcerations. Ar-
ticular cartilages harvested after 8 weeks from ACLT and stained with
Safranin-O clearly showed a superﬁcial ﬁbrillation with microscopic cracks
and proteoglycan depletion in the cartilage matrix particularly in the
medial condyle. At 3 and 6 months the untreated cartilage presented
the progression of OA process with evident signs of matrix loss extended
to deep zones of cartilage and particular evident in the medial condyle.
The animals treated with MSCs-HA scaffolds showed a better matrix
organization, a higher presence of proteoglycan component and normal
distribution of the cells together with an increase in collagen II expression
in comparison with rabbits treated with HA scaffold alone or the untreated
groups. In the animals treated with MSCs-HA scaffolds histomorfometric
parameters showed a decrease of modiﬁed Mankin score after 3 and
6 months after the treatment.
Conclusions: The present study demonstrates that the use of MSCs
loaded on a HA scaffold can contribute to the regeneration of a new
cartilage tissue in a rabbit model of OA. It is possible to speculate that
the beneﬁcial effects of MSCs might reﬂect, in part, some trophic and
protective activities they exert on injuried cells and tissue, togheter with
their property to differentiate into chondrocytic lineage.
